Oncology patients are at a high risk of experiencing venous thromboembolism. Historically, venous thromboembolisms in cancer patients have been managed with low-molecular-weight heparin on the basis of the CLOT trial published in 2003. However, recent prospective data provide evidence for safe and effective direct oral anticoagulant use in this population. The purpose of this review article is to evaluate the current body of literature surrounding direct oral anticoagulant use in the oncology population and to highlight key practical considerations when prescribing these agents for patients with cancer.
LeeAYLevineMN.Venous thromboembolism and cancer: risks and outcomes.Circulation2003;
107(23_suppl_1): 1–17.
2.
VoigtlaenderMLangerF.Management of cancer-associated venous thromboembolism—a case-based practical approach.Vasa2018; 47: 77–89.
3.
LeeAYLevineMNBakerRI, et al.
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.New Engl J Med2003;
349: 146–153.
4.
KearonCAklEAOrnelasJ, et al.
Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report.Chest2016;
149: 315–352.
5.
StreiffMBHolmstromBAshraniA, et al.
Cancer-associated venous thromboembolic disease, version 1.2019. J Natl Comprehen Cancer Network2019; 16: 1289–1303.
6.
MandalaMFalangaARoilaF, et al.
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines.Ann Oncol2011;
22(suppl_6): vi85–vi92.
7.
Lyman GH, Bohlke K, Khorana AA, et al.
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014.J Clin Oncol2015;
33: 654.
8.
MazzolaiLAboyansVAgenoW, et al.
Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European society of cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function.Eur Heart J2017;
39: 4208–4218.
9.
KhoranaAAYannicelliDMcCraeKR, et al.
Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed?Thrombosis Res2016;
145: 51–53.
10.
BrunettiNDGesueteEDe GennaroL, et al.
Direct oral anti-coagulants compared with vitamin-K inhibitors and low-molecular-weight-heparin for the prevention of venous thromboembolism in patients with cancer: a meta-analysis study.Int J Cardiol2017;
230: 214–221.
11.
van EsNCoppensMSchulmanS, et al.
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.Blood2014;
124: 1968–1975.
12.
RaskobGBüllerHSegersA.Edoxaban for cancer-associated venous thromboembolism.New Engl J Med2018;
379: 95–96.
13.
YoungAMMarshallAThirlwallJ, et al.
Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36: 2017–2023.
14.
McBaneRDWysokinskiWELe-RademacherJ, et al. Apixaban, dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial. Thromb Haemost. Epub ahead of print 20 October 2019. DOI: 10.1111/jth.14662.
15.
AgnelliGBecattiniCBauersachsR, et al.
Apixaban versus dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio Study.Thromb Haemost2018;
118: 1668–1678.
16.
LiAGarciaDALymanGH, et al.
Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis.Thrombosis Res2019;
173: 158–163.
17.
KeyNSKhoranaAAKudererNM, et al.
Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update.J Clin Oncol. Epub ahead of print 5 August 2019. DOI: 10.1200/JCO.19.01461.
18.
KhoranaAANobleSLeeAY, et al.
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.J Thromb Haemost2018;
16: 1891–1894.
19.
KraaijpoelNDi NisioMMulderFI, et al.
Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer Study.Thromb Haemost2018;
118: 1439–1449.
20.
EscalanteJMcQuadeRMStojanovskaV, et al.
Impact of chemotherapy on gastrointestinal functions and the enteric nervous system.Maturitas2017; 105: 23–29.
21.
WeinstockMJUhlmannEJZwickerJI.Intracranial hemorrhage in cancer patients treated with anticoagulation.Thromb Res2016;
140: S60–S65.
22.
GerberDEGrossmanSAStreiffMB.Management of venous thromboembolism in patients with primary and metastatic brain tumors.J Clin Oncol2006;
24: 1310–1318.
23.
MantiaCUhlmannEJPuligandlaM, et al.
Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin.Blood2017;
129: 3379–3385.
24.
ZwickerJIKarp LeafRCarrierM.A meta‐analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation.J Thromb Haemost2016;
14: 1736–1740.
25.
KhouryMNMissiosSEdwinN, et al.
Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism.Neuro-oncol Pract2015;
3: 87–96.
26.
CarneyBJUhlmannEJPuligandlaM, et al.
Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors.J Thromb Haemost2019;
17: 72–76.
27.
ReillyPALehrTHaertterS, et al.
The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy).J Am Coll Cardiol2014;
63: 321–328.
28.
UpretiVVWangJBarrettYC, et al.
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects.Br J Clin Pharm2013;
76: 908–916.
29.
KubitzaDBeckaMZuehlsdorfM, et al.
Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59‐7939) in healthy subjects.J Clin Pharm2007;
47: 218–226.
30.
MartinKBeyer‐WestendorfJDavidsonBL, et al.
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.J Thromb Haemost2016;
14: 1308–1313.
31.
ConwaySEHwangAYPonteCD, et al.
Laboratory and clinical monitoring of direct acting oral anticoagulants: what clinicians need to know.Pharmacother J Human Pharmacol Drug Ther2017;
37: 236–248.
32.
MueckWBorrisLCDahlOE, et al.
Population pharmacokinetics and pharmacodynamics of once and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement.Thromb Haemost2008;
100: 453–461.
33.
BullerHRLensingAWPrinsMH, et al.
A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging Study.Blood2008;
112: 2242–2247.
34.
FavaloroEJLippiG.The new oral anticoagulants and the future of haemostasis laboratory testing.Biochem Med Biochem Med2012;
22: 329–341.
35.
DagerWEGosselinRCKitchenS, et al.
Dabigatran effects on the international normalized ratio, activated partial thromboplastin time, thrombin time, and fibrinogen: a multicenter, in vitro study.Ann Pharmacother2012;
46: 1627–1636.
36.
SamamaMMMartinoliJLLeFlemL, et al.
Assessment of laboratory assays to measure rivaroxaban—an oral, direct factor Xa inhibitor.Thromb Haemost2010;
103: 815–825.
37.
ConnollySJMillingTJ JrEikelboomJW, et al.
Andexanet alfa for acute major bleeding associated with factor Xa inhibitors.New Engl J Med2016;
375: 1131–1141.
38.
SiegalDMCurnutteJTConnollySJ, et al.
Andexanet alfa for the reversal of factor Xa inhibitor activity.New Engl J Med2015;
373: 2413–2424.
39.
PiranSKhatibRSchulmanS, et al.
Management of direct factor Xa inhibitor–related major bleeding with prothrombin complex concentrate: a meta-analysis.Blood Adv2019;
3: 158–167.
40.
JuliaSJamesU.Direct oral anticoagulants: a quick guide.Eur Cardiol Rev2017;
12: 40.
41.
StacyZACallWBHartmannAP, et al.
Edoxaban: a comprehensive review of the pharmacology and clinical data for the management of atrial fibrillation and venous thromboembolism.Cardiol Ther2016;
5: 1–8.
Product information:SAVAYSA (edoxaban), tablets for oral use.
Daiichi Sankyo, Inc.
Parsippany, NJ, 2015.
44.
VranckxPValgimigliMHeidbuchelH.The significance of drug–drug and drug–food interactions of oral anticoagulation.Arrhythm Electrophysiol Rev2018;
7: 55.
45.
SteffelJVerhammePPotparaTS, et al.
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.Eur Heart J2018;
39: 1330–1393.
46.
RiessHAyCBauersachsR, et al.
Use of direct oral anticoagulants in patients with cancer: practical considerations for the management of patients with nausea or vomiting.Oncologist2018;
23: 822–839.
PetersonJJHoehnsJD.Administration of direct oral anticoagulants through enteral feeding tubes.J Pharm Technol2016;
32: 196–200.
49.
HakeamHA andAl-SaneaN.Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs).J Thromb Thrombol2017;
43: 343–351.
50.
MolnarAOBotaSEGargAX, et al.
The risk of major hemorrhage with CKD.J Am Soc Nephrol2016;
27: 2825–2832.
51.
MunozFDGharacholouSMMungerTM, et al.
Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation.Am J Cardiol2016;
117: 69–75.
52.
ChangMYuZShenkerA, et al.
Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban.J Clin Pharmacol2016;
56: 637–645.
53.
MavrakanasTASamerCFNessimSJ, et al.
Apixaban pharmacokinetics at steady state in hemodialysis patients.J Am Soc Nephrol2017;
28: 2241–2248.
54.
DohertyJUGluckmanTJHuckerWJ, et al.
2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force.J Am Coll Cardiol2017;
69: 871–898.
